It is a harrowing proposition: that in trying to control drug prices for 67 million Medicare patients now, we might inadvertently prevent the development of future drugs that could save lives. Implied, if not stated outright, is that we’re putting a cure for cancer or Alzheimer’s or some other intractable disease in jeopardy.

But we have good reasons to believe that the current policy won’t have such a trade-off any time soon. For one, pharma is hugely profitable, and these negotiated prices, while potentially chipping away at profit margins, should hardly entirely dampen the incentive to innovate, according to a couple of key studies of the industry. Two, if we are worried about future innovation, we should be focused on making it cheaper to develop drugs – and this is actually one area where AI is showing promise. By identifying the best candidates for possible treatments early in the research process, we could speed up development and continue to reduce costs — without losing out on tomorrow’s breakthroughs. …

  • @[email protected]
    link
    fedilink
    English
    164 months ago

    Without price controls only the rich will be able to afford those “miracle” cures anyway.

    • @[email protected]
      link
      fedilink
      English
      64 months ago

      This hits the point already. Look at those weight loss drugs that help people lose weight and are needed by certain other people.

      Look at all the celebrities all of a sudden on them and regular people’s insurance won’t cover them. The regular folks who need them have trouble getting them as a result.